7498 Results (Page 202 of 300)
Pharmaceuticals Markets Research Reports
Canada Age-Related Macular Degeneration Therapeutics Market Analysis
The Canada Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $0.86 Bn in 2022, and is predicted to grow at a CAGR of 8.9% from 2023 to 2030, to US $1.71 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, advancements in diagnostic technologies, and other factors. The industry is primarily dominated by players such as Genentech, Novartis, Bayer, Roche, and Ocular Therapeutics, among others
US Alexipharmic Drugs Market Analysis
US Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 2.70% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The US Alexipharmic Drugs market will grow because of the rising prevalence of various forms of chronic conditions and overdosing on prescription medications. The key market players are Pfizer Inc. (USA), Bristol-Myers Squibb Company (USA), Mylan N.V. (USA), and others.
UK Obesity Drugs Market Analysis
This report presents a strategic analysis of the UK Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the UK Obesity Drugs Market, offering unmatched value, accuracy, and expert insights.
UK Cardiovascular Diseases Therapeutics Market Analysis
UK's cardiovascular disease therapeutics market is projected to grow from $4.22 Bn in 2022 to $6.35 Bn in 2030 with a CAGR of 5.22% for the year 2022-30. Cardiovascular disease remains the major cause of death in the UK, also the development of new drugs for the treatment of cardiovascular diseases in the UK is the major growth driver of the market. The UK cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by end user. Ackerley Pharma, eXmoor Pharma, and Bristol-Myers Squibb are the major players in the UK cardiovascular disease therapeutics market.
China Alcohol Addiction Therapeutics Market Analysis
The China Alcohol Addiction Therapeutics Market is valued at around $58 Mn in 2022 and is projected to reach $105 Mn by 2030, exhibiting a CAGR of 7.8% during the forecast period. The primary growth drivers in the China Alcohol Addiction Therapeutic Market are the escalating prevalence of Alcohol Addiction due to rising disposable income and sociocultural shifts, expanding treatment options, and government initiatives recognizing AUD as a public health concern. The key players involved in the research, development, and distribution of Alcohol Addiction Therapeutics in China are Merck & Co., Alkermes, TEVA, Otsuka Pharmaceuticals, Adial Pharmaceuticals, Yabao Pharmaceutical, Tasly Pharmaceutical, China Meheco Corporation, Tonghua Dongbao, Harbin Pharm etc.
Canada Alcohol Addiction Therapeutics Market Analysis
The Canada Alcohol Addiction Therapeutics Market is valued at around $57 Mn in 2022 and is projected to reach $93 Mn by 2030, exhibiting a CAGR of 6.3% during the forecast period. The Increasing public awareness, government support, and advancements in research and innovation are driving the destigmatization of alcohol addiction, fostering greater acceptance of mental health, and fueling the demand for more accessible and personalized treatment options, thus increasing market growth. The key players involved in the research, development, and distribution of alcohol addiction therapeutics in Canada are AbbVie, AstraZeneca, Roche, Bausch Health, Pfizer, Otsuka, Alkermes, Ethypharm, Biovail, Beacon etc among others.
Brazil Alcohol Addiction Therapeutics Market Analysis
The Brazil Alcohol Addiction Therapeutics Market is valued at around $18 Mn in 2022 and is projected to reach $31 Mn by 2030, exhibiting a CAGR of 7.3% during the forecast period. The intensified commitment of the Brazilian government to mental health, coupled with the urbanization-induced surge in alcohol consumption, is fuelling a rising need for treatment solutions. The key players involved in the research, development, and distribution of Alcohol Addiction Therapeutics in Brazil are Alkermes, TEVA, Otsuka, GlaxoSmithKline, BioCorRx, Adial Pharmaceuticals, Kinnov Therapeutics, Opiant, MediciNova, Corcept Therapeutics, among others
Spain Age-Related Macular Degeneration Therapeutics Market Analysis
The Spain Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $208 Mn in 2022 and is predicted to grow at a CAGR of 7.90% from 2023 to 2030, to US $383 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, advancements in treatment, and other factors. Major players in the industry include Regeneron Pharmaceuticals, Novartis, Bayer, Roche, Genentech, and other notable companies
Kenya Cardiovascular Drugs Market Analysis
Kenya Cardiovascular Drug Market is at around $0.1 Bn in 2022 and is projected to reach $1.4 Bn in 2030, exhibiting a CAGR of 4.9% during the forecast period. Increased burden of cardiovascular diseases, government support & policies, and increased public awareness are driving the growth of the market. The market is dominated by key players like Regal Pharmaceuticals (KEN), Transwide Pharmaceuticals (KEN), Bristol-Myers Squibb Co., F. Hoffman-La Roche, Pfizer Inc., Astra Zeneca, Merck & Co., Sanofi, Novartis, and GSK.
Mexico Cardiovascular Drugs Market Analysis
Mexico Cardiovascular Drug Market is at around $2.1 Bn in 2022 and is projected to reach $2.9 Bn in 2030, exhibiting a CAGR of 4.05% during the forecast period. Increased prevalence of disease, greater awareness, and strategic partnerships between pharmaceutical companies and healthcare providers are driving the market. The market is dominated by key players like Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.
India Cardiovascular Drugs Market Analysis
India Cardiovascular Drug Market is at around $2.52 Bn in 2022 and is projected to reach $4.26 Bn in 2030, exhibiting a CAGR of 6.8% during the forecast period. The main market drivers include changing lifestyles that result in a higher prevalence of cardiovascular illnesses including hypertension. The market is dominated by key players like Cipla (IND), Torrent Pharmaceuticals (IND), Glenmark Pharmaceuticals (IND), Sun Pharmaceutical Industries (IND), Dr. Reddy's Laboratories (IND), Lupin (IND), Aurobindo Pharma (IND), Cadila Healthcare (IND), Wockhardt (IND), and Alembic Pharmaceuticals (IND).
Italy Cardiovascular Drugs Market Analysis
Italy Cardiovascular Drug Market is at around $3.32 Bn in 2022 and is projected to reach $4.31 Bn in 2030, exhibiting a CAGR of 3.3% during the forecast period. Italy's robust healthcare system facilitates more access to advanced, efficacious cardiovascular drugs, hence propelling market expansion. The market is dominated by key players like Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.
Hong Kong Cardiovascular Drugs Market Analysis
Hong Kong Cardiovascular Drug Market is at around $0.22 Bn in 2022 and is projected to reach $0.32 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period. Access to healthcare services, technology advancements, and patient demographics are the main drivers of this industry's growth. The market is dominated by key players like Kalbe Pharma, Kimia Pharma, Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, and Gilead Sciences, Inc. Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffmann-La Roche Ltd.
Thailand Cardiovascular Drugs Market Analysis
Thailand Cardiovascular Drug Market is at around $0.2 Bn in 2022 and is projected to reach $0.23 Bn in 2030, exhibiting a CAGR of 4.14% during the forecast period. Aging population, rise in cardiovascular diseases, and adoption of unhealthy lifestyle is propelling the market growth. The market is dominated by key players Silom Medical, Paradigm Pharma (THA), OLIC (THA), Interthai Pharmaceutical (THA), Pfizer Inc., Novartis, Sanofi, Astra Zeneca, Merck & Co., Zydus, and Lupin.
Netherlands Cardiovascular Drugs Market Analysis
Netherlands Cardiovascular Drug Market is at around $0.4 Bn in 2022 and is projected to reach $0.5 Bn in 2030, exhibiting a CAGR of 4.3% during the forecast period. Increased elderly population, healthcare accessibility, and healthcare spending & affordability in the country are driving the growth of the market. The market is dominated by key players like Pfizer Inc., Novartis, Sanofi, Merck & Co., Astra Zeneca, Daiichi Sankyo, Takeda Pharmaceutical, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, and Bayer AG.
Egypt Cardiovascular Drugs Market Analysis
Egypt Cardiovascular Drug Market is at around $0.4 Bn in 2022 and is projected to reach $0.6 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. The market is expanding as a result of government initiatives, increased access to health insurance, and a rise in cardiovascular load. The market is dominated by key players like Copad Pharma, Menarini Pharmaceutical, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffman-La Roche, Pfizer Inc., Astra Zeneca, Sanofi, Novartis, and GSK.
Vietnam Cardiovascular Drugs Market Analysis
Vietnam Cardiovascular Drug Market is at around $0.7 Bn in 2022 and is projected to reach $0.95 Bn in 2030, exhibiting a CAGR of 4.03% during the forecast period. The market is growing due to an increase in cardiovascular burden, rising awareness for healthcare, and improved healthcare infrastructure. The market is dominated by key players like Ha Tay Pharmaceutical, OPC Pharmaceutical, ImexPharm, Binh Dinh Pharmaceutical, Mylan and Teva, Sun Pharmaceutical, F. Hoffman-La Roche, Pfizer Inc., Astra Zeneca, Sanofi, Novartis, and GSK.
UK Cardiovascular Drugs Market Analysis
UK Cardiovascular Drug Market is at around $3.56 Bn in 2022 and is projected to reach $4.15 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period. Government initiatives to promote cardiovascular health and implement preventative measures may result in an increase in the market for cardiovascular medications. The market is dominated by key players like Bristol-Myers Squibb Co, Pfizer, Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca Inc., Sanofi-Aventis Inc., Novartis Pharmaceuticals, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.
UAE Cardiovascular Drugs Market Analysis
UAE Cardiovascular Drug Market is at around $0.67 Bn in 2022 and is projected to reach $1.01 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period. Major reasons propelling the growth of this market are technological advancements, health insurance coverage, and partnerships with other pharmaceutical industries. The market is dominated by key players like Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.
Saudi Arabia Cardiovascular Drugs Market Analysis
Saudi Arabia Cardiovascular Drug Market is at around $2.4 Bn in 2022 and is projected to reach $3.6 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. The market is propelling due to factors such as government initiatives & early detection of the disease, rising levels of disposable income in the country, and adoption of unhealthy lifestyle patterns. The market is dominated by key players like Tabuk Pharmaceuticals, Jamjoom Pharma, Pfizer Inc., Novartis, Sanofi, Merck & Co., Astra Zeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, and Bayer AG.
Japan Cardiovascular Drugs Market Analysis
Japan Cardiovascular Drug Market is at around $8.56 Bn in 2022 and is projected to reach $12.04 Bn in 2030, exhibiting a CAGR of 4.30% during the forecast period. Due to changes in modern lifestyle, the prevalence of cardiovascular disease has been rising. The market is dominated by key players like Otsuka Holdings Co Ltd., Takeda Pharmaceutical Co Ltd., Daiichi Sankyo Co Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, and Novartis AG.
Germany Cardiovascular Drugs Market Analysis
Germany Cardiovascular Drug Market is at around $5.06 Bn in 2022 and is projected to reach $5.93 Bn in 2030, exhibiting a CAGR of 2% during the forecast period. The incidence of cardiovascular diseases and increased public awareness of cardiovascular health drive market growth. The market is dominated by key players like Bristol-Myers Squibb Co, Pfizer, Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca Inc., Sanofi-Aventis Inc., Novartis Pharmaceuticals, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.
France Cardiovascular Drugs Market Analysis
France Cardiovascular Drug Market is at around $3.8 Bn in 2022 and is projected to reach $4.74 Bn in 2030, exhibiting a CAGR of 2.8% during the forecast period. Wider access to cutting-edge, efficient cardiovascular medications is made possible by France's strong healthcare system, which drives market expansion. The market is dominated by key players like Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.
China Cardiovascular Drugs Market Analysis
China Cardiovascular Drug Market is at around $11.12 Bn in 2022 and is projected to reach $16.81 Bn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The adoption of digital healthcare is a key factor driving the rise of the China Cardiovascular Drugs Market. The market is dominated by key players like Shanghai Fosun Pharmaceutical Group Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis, and Merck & Co., Inc.
UAE Vitamin and Minerals Market Analysis
This report presents a strategic analysis of the UAE Vitamin and Minerals Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the UAE Vitamin and Minerals Market, offering unmatched value, accuracy, and expert insights.
